Amgen Breaks Ground On Next-Generation Biomanufacturing Plant In Rhode Island
The Plant Will be First-of-its-Kind in the U.S. THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets. "Biologics manufacturing is a complex science and has long been a competitive advantage for Amgen," said Robert A. Bradway, chairman and chief...
Source: Amgen News Release - July 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2018 Third Quarter Dividend
THOUSAND OAKS, Calif., July 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the third quarter of 2018. The dividend will be paid on Sept. 7, 2018, to all stockholders of record as of the close of business on Aug. 17, 2018. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and unders...
Source: Amgen News Release - July 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Succession Plans For Two Executive Officers
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ:AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today. After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology at Amgen,...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion. Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth. GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares o...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast of 2018 Second Quarter Financial Results
THOUSAND OAKS, Calif., July 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2018 financial results on Thursday, July 26, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2:00 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investo...
Source: Amgen News Release - July 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Cedars-Sinai Partner For Improved Healthcare Quality
First Amgen Collaboration With Academic Medical Center Focused on Research, Health Service Redesign and Outcomes-Based Care THOUSAND OAKS, Calif. and LOS ANGELES, July 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Cedars-Sinai Medical Center today announced a partnership to help support the improvement of healthcare quality in the treatment of multiple therapeutic areas that could include oncology, cardiovascular disease, osteoporosis and migraine. The organizations intend to jointly undertake research projects in one or more of these therapeutic areas. They also plan to focus on projects that could achieve be...
Source: Amgen News Release - July 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Former Major League Baseball (MLB) All-Stars Dave Winfield And Steve Garvey Team Up With Amgen To Launch Myeloma MVP ™ And Encourage Patients To Create Their Most Valuable Plan For Managing Multiple Myeloma
Discussion With Doctor to Create Individualized Treatment Plan Don Baylor Jr., Son of Former MLB Most Valuable Player Don Baylor, Honors Late Father's Legacy by Raising Multiple Myeloma Awareness Through Campaign Amgen to Recognize Local Multiple Myeloma Communities at Select MLB Games in 2018 THOUSAND OAKS, Calif., July 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the launch of Myeloma MVPTM, a national campaign to help those affected by multiple myeloma create their Most Valuable Plan, an individualized approach for managing their disease. Multiple myeloma is an incurable blood ... (Source: Amgen News Release)
Source: Amgen News Release - July 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY ™ (romosozumab) To The US FDA
BLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 Patients THOUSAND OAKS, Calif. and BRUSSELS, July 12, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the resubmission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY™* (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk for fracture. EVENITY increases bone formation and reduces bone resorption simultaneously to increase bone mineral density (BMD) and reduce the risk of fracture. ...
Source: Amgen News Release - July 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen and MBC Biolabs Announce Winners of the Amgen Golden Ticket
Two Biotherapeutic Companies Receive Lab Space and Other Benefits at Bay Area Life Sciences IncubatorTHOUSAND OAKS, Calif. and SAN FRANCISCO (June 29, 2018) - Amgen (NASDAQ:AMGN) and MBC BioLabs (formerly QB3@953) announced today that Delve Therapeutics and Mitokinin have won the Amgen Golden Ticket at MBC BioLabs. Each company receives one year of lab bench space and access to core facilities at the MBC BioLabs life sciences incubator, as well as connections to Amgen’s scientific and business leaders to help advance its scientific programs. Amgen first sponsored MBC BioLabs in 2015 to assist high-potential...
Source: Amgen News Release - June 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig ™ (erenumab-aooe) In Patients With Chronic And Episodic Migraine
Results From a One-Year Study of Efficacy and Safety of Aimovig in Chronic Migraine and Data From a Three-Year Analysis Assessing Safety and Tolerability of Aimovig in Episodic Migraine Will be Presented at the American Headache Society Annual Meeting Aimovig Showed Robust Efficacy in Patients With Chronic Migraine, With Reductions in Monthly Migraine Days Sustained Throughout the Study Established Safety Profile of Aimovig Reinforced With Chronic and Episodic Migraine Data THOUSAND OAKS, Calif., June 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the results of tw...
Source: Amgen News Release - June 28, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Health And Benefits Consultant Piper Jordan Partner On First Migraine Project With Employers
$11 Billion is Estimated to be Lost by American Employers Each Year Due to Migraine Collaboration Underscores Amgen's Commitment to Reducing Migraine Stigma in the Workplace THOUSAND OAKS, Calif. and SAN DIEGO, June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Piper Jordan, one of the nation's leading health and benefits consulting firms, today announced a unique partnership to help improve health and well-being in the workplace for people living with migraine. The collaboration aims to provide disease management resources to both the employee and employer through innovative educational programs, ...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Novartis Highlight Findings From A Large Global Patient Survey Revealing That Worldwide Approximately 60 Percent Of Employed People With Migraine Missed, On Average, A Week Of Work In A Month
The My Migraine Voice Survey Involved More Than 11,000 People Globally, 10 Percent of Which Were From the U.S., and Highlights Urgent Need for Better Care for Benefit of Patients and Society In the U.S., Patients Reported Eighty Percent of Employers Knew About Their Migraine, but Only 21 Percent Offered Support Migraine is Estimated to Cost Up to $22 Billion in the U.S. Annually, Including Indirect Costs Such as Lost Productivity; Survey Finds 18 Percent of Worktime is Missed Due to Migraine in the U.S. THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced initial findings f...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Top-Line Results From Phase 3 Study Of ABP 710, Biosimilar Candidate To Infliximab
Study Evaluated Efficacy and Safety of ABP 710 Compared With Infliximab in Patients With Moderate-to-Severe Rheumatoid Arthritis Amgen to Seek Regulatory Approvals THOUSAND OAKS, Calif., June 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 710 compared with REMICADE® (infliximab) in patients with moderate-to-severe rheumatoid arthritis. The results confirm non-inferiority compared to infliximab but could not rule out superiority based on its primary efficacy endpoint, which compared the response differen...
Source: Amgen News Release - June 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Data Show Amgen's Repatha ® (evolocumab) Significantly Reduced LDL-C And Non-HDL-C In High-risk Patients With Type 2 Diabetes
Data Presented at the 78th Scientific Sessions of the American Diabetes Association THOUSAND OAKS, Calif., June 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data that show Repatha® (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with Type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. BANTING was a dedicated study evaluating the efficacy of Repatha (monthly dosing), in lowering LDL-C and improving o...
Source: Amgen News Release - June 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives European Commission Approval To Add Overall Survival Data To BLINCYTO ® (blinatumomab) Label
BLINCYTO is the First-and-Only Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Immunotherapy THOUSAND OAKS, Calif., June 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has granted a full marketing authorization for BLINCYTO® (blinatumomab) based on the overall survival (OS) data from the Phase 3 TOWER study in adult patients with Philadelphia chromosome-negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). "BLINCYTO is the first single agent immunotherapy to demonstrate superior overall survival benefit ov...
Source: Amgen News Release - June 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid tre...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Goldman Sachs 39th Annual Global Healthcare Conference
THOUSAND OAKS, Calif., June 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 39th Annual Global Healthcare Conference at 9:30 a.m. PT on Tuesday, June 12, 2018, in Rancho Palos Verdes, Calif. Elliott M. Levy, M.D., senior vice president of Research and Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the pote...
Source: Amgen News Release - June 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen, Oklahoma Health Care Authority And University of Oklahoma's Pharmacy Management Consultants Partner To Improve Medicaid Outcomes
Amgen's First Public-Private Partnership with a State Medicaid Agency to Help Improve Patient Health Care Needs Through Data, Science and Information THOUSAND OAKS, Calif. and OKLAHOMA CITY, June 6, 2018 /PRNewswire/ -- The Oklahoma Health Care Authority (OHCA), Pharmacy Management Consultants (PMC) and Amgen (NASDAQ:AMGN) today announced a new collaborative agreement to help improve clinical outcomes, experience and satisfaction for Oklahoma's 796,000 SoonerCare (Oklahoma Medicaid) members. Results from the projects also could lay the groundwork for innovative ways to look at patient outcomes and measures f...
Source: Amgen News Release - June 6, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Preventing Infections in Cancer Patients Program to Launch Innovative Tools to Improve Patient-Provider Conversations
CDC  Foundation Program, Supported by Amgen, Will Launch New Virtual Simulation Mobile  Apps and Spanish-Language Website This SummerInitiated  in 2009, the Program is Instrumental in Providing Key Resources for Patients,  Caregivers and Healthcare Professionals to Improve Infection Control During  Cancer TreatmentATLANTA (June 5th, 2018) — The CDC Foundation and Amgen today announced several new  initiatives that will be available this summer as part of the Preventing  Infections in Cancer Patients (PICP) program. The PICP program has been  supported by Amgen and led by the Ce...
Source: Amgen News Release - June 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS ® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today During Oral Session at ASCO 2018 and Simultaneously Published in The Lancet Oncology THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-...
Source: Amgen News Release - June 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And MD Anderson Announce Collaboration To Accelerate Early Stage Treatments For Leukemia, Myelodysplastic Syndromes, Multiple Myeloma, Small-Cell Lung And Other Small-Cell Cancers
Efforts to Focus on Pre-Clinical and Clinical Research for up to 16 Early-Stage Programs Across Various Types of Cancer Multi-Year Agreements Build on Long-Term Partnership in Immuno-Oncology, Including BiTE® Therapies and now CAR T Programs THOUSAND OAKS, Calif. and HOUSTON, May 31, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and The University of Texas MD Anderson Cancer Center today announced two multi-year collaboration agreements aimed at accelerating development of a variety of Amgen's early-stage oncology therapies for patients with leukemia, myelodysplastic syndromes, multiple myeloma, small-cell lung ...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation And Harvard Team Up To Offer Free Online Science Education Platform
LabXchange Will Provide Virtual Lab Experiences Integrating Digital Instruction With Collaboration and Mentoring Opportunities Interactive Platform Levels Playing Field for Aspiring Scientists Amgen Foundation Contributes $6.5 Million as Founding Sponsor Technology Built on Open-Source edX Platforms THOUSAND OAKS, Calif. and CAMBRIDGE, Mass., May 30, 2018 /PRNewswire/ -- The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a foc...
Source: Amgen News Release - May 31, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Foundation and Harvard Team Up To Offer Free Online Science Education Platform
LabXchange Will Provide Virtual Lab Experiences Integrating Digital Instruction With Collaboration and Mentoring OpportunitiesInteractive Platform Levels Playing Field for Aspiring Scientists Amgen Foundation Contributes $6.5 Million as Founding SponsorTechnology Built on Open-Source edX PlatformsTHOUSAND OAKS, Calif. and CAMBRIDGE, Mass. – (May 30, 2018) – The Amgen Foundation and Harvard University today announced plans to launch a free online science education platform uniquely designed to level the playing field for aspiring scientists. The LabXchange platform, which will launch with a focus in biology, wil...
Source: Amgen News Release - May 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
Public-Private Partnership Aims to Connect Underserved Cancer Patients to Enhanced Symptom Management Support Through the Use of Connected Technologies THOUSAND OAKS, Calif., May 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a groundbreaking collaboration with the National Cancer Institute (NCI), the Federal Communications Commission (FCC) Connect2Health Task Force, the University of Kentucky (UK) Markey Cancer Center and the University of California, San Diego (UCSD) Design Lab to support the improvement of cancer outcomes. The L.A.U.N.C.H. (Linking & Amplifying User-Centered Networks through ...
Source: Amgen News Release - May 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Voting Results Of Annual Meeting Of Stockholders
THOUSAND OAKS, Calif., May 22, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif. Approximately 90 percent of outstanding shares were represented at the meeting. The director nominees Wanda M. Austin, Robert A. Bradway, Robert A. Eckert, Greg C. Garland, Fred Hassan, Rebecca M. Henderson, Frank C. Herringer, Charles M. Holley, Jr., Tyler Jacks, Ellen J. Kullman, Ronald D. Sugar, and R. Sanders Williams were each re-elected to Amgen's Board of Directors. Brian J. Druker, a new nominee for director, wa...
Source: Amgen News Release - May 22, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Prolia ® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Fifth Indication for Prolia for Men and Women at High Risk of Fracture Receiving Systemic Glucocorticoid Therapy THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data...
Source: Amgen News Release - May 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Aimovig ™ (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
Migraine is a Severe Neurologic Disease That Profoundly Impacts Millions of Patients in the United States Aimovig is the First and Only FDA-Approved Treatment to Block the Calcitonin Gene-Related Peptide Receptor (CGRP-R), Which Plays an Important Role in Migraine Aimovig was Consistently Shown to Reduce Monthly Migraine Days, Including in More Difficult-to-Treat Populations, With Many Patients Achieving at Least a 50 Percent Reduction THOUSAND OAKS, Calif., May 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-...
Source: Amgen News Release - May 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives European Commission Approval For Repatha ® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
New Indication Supports Amgen's Commitment to Reduce the Risk of Recurrent Cardiovascular Events Faced by Heart Attack and Stroke Survivors Amgen Announces Efforts to Improve Repatha's Affordability Across Europe for Payers who Significantly Expand Patient Access THOUSAND OAKS, Calif., May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by ...
Source: Amgen News Release - May 16, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
THOUSAND OAKS, Calif., May 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch 2018 Health Care Conference at 10 a.m. PT on Tuesday, May 15, 2018. David W. Meline, executive vice president and chief financial officer at Amgen, and David M. Reese, senior vice president of Translational Sciences and Oncology at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. Ab...
Source: Amgen News Release - May 10, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia ® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture THOUSAND OAKS, Calif., April 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. "Today's positive opinion by the CHMP is an important step for Prolia in help...
Source: Amgen News Release - April 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports First Quarter 2018 Financial Results
THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent versus the first quarter of 2017 to $5.6 billion. Product sales grew 3 percent globally. All new and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 16 percent to $3.25 driven by higher product sales, a lower tax rate and lower weighted-average shares...
Source: Amgen News Release - April 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Webcast Of 2018 First Quarter Financial Results
THOUSAND OAKS, Calif., April 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2018 financial results on Tuesday, April 24, 2018, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. PT. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team. Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors ...
Source: Amgen News Release - April 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig ™ (erenumab) For Migraine Patients With Multiple Treatment Failures
The LIBERTY Trial was Conducted in Patients who Have Tried Two to Four Therapies Without Success -- a Uniquely Difficult-to-Treat Population Often Excluded From Migraine Prevention Trials Patients Taking Aimovig had Nearly Three-Fold Higher Odds of Having Their Migraine Days cut by Half or More Compared to Placebo Safety and Tolerability Were Consistent With Results Seen in the Pivotal Clinical Program; Over 97 Percent of Those Taking Aimovig Completed the Double-Blind Treatment Phase Data Selected by the American Academy of Neurology Science Committee as one of the Most Noteworthy Presentations at 2018 Annual Meetin...
Source: Amgen News Release - April 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
Revolutionary, Innovative Plant Offers Greater Flexibility, Speed and Efficiency THOUSAND OAKS, Calif., April 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced plans to build a new state-of-the-art next-generation biomanufacturing plant at its campus in West Greenwich, R.I. The new plant, the first of its kind in the United States (U.S.), will employ Amgen's proven next-generation biomanufacturing capabilities and manufacture products for the U.S. and global markets. A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built ...
Source: Amgen News Release - April 10, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
First Data Presentations for CAR T Programs, Including DLL3 in Small Cell Lung Cancer and FLT3 in Acute Myeloid Leukemia Pre-Clinical Data Evaluating Half-Life Extended Anti-BCMA BiTE® Presented for First-Time New Data Include two Studies Investigating Mcl-1 Inhibitor AMG 176 THOUSAND OAKS, Calif., April 9, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new pre-clinical data for several of its novel investigational oncology candidates will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago, April 14-18, 2018. Data spans Amgen's ...
Source: Amgen News Release - April 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

European Commission Approves Expanded Indication For Amgen's XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients THOUSAND OAKS, Calif., April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone. The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma. The approval is based on data from the Phase 3 '482 study, the largest internat...
Source: Amgen News Release - April 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves BLINCYTO ® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
BLINCYTO is the First-and-Only FDA-Approved Therapy for Minimal Residual Disease Detection of Remaining Cancer Cells After Complete Remission is the Strongest Prognostic Factor for Relapse in Patients With Acute Lymphoblastic Leukemia Accelerated Approval Based on Data From the Phase 2 BLAST Study, the Largest Prospective Trial in Minimal Residual Disease-Positive Acute Lymphoblastic Leukemia THOUSAND OAKS, Calif., March 29, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO® (bl...
Source: Amgen News Release - March 29, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion Recognizing That Repatha ® (evolocumab) Prevents Heart Attacks And Strokes
Recommended Label Includes New Indication Based on the Repatha Cardiovascular Outcomes Study (FOURIER) Amgen Continues to Work Closely With Payers on a Country-by-Country Basis to Ensure Access to Repatha for High-Risk Cardiovascular Patients THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to include a new indication in the Repatha® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarc...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen And Allergan Receive Positive CHMP Opinion For ABP 980 (Biosimilar Herceptin ®) For The Treatment Of Three Types Of Cancer
Recommended for Approval for the Same Indications as Herceptin® (Trastuzumab) Positive Opinion for ABP 980 is Supported by Phase 3 Data in Patients With HER2-Postive Early Breast Cancer THOUSAND OAKS, Calif., March 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of ABP 980, a biosimilar to Herceptin® (trastuzumab). ABP 980 has been recommended for approval for the treatment of the same three types of...
Source: Amgen News Release - March 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events
Research Presented at American College of Cardiology's 67th Annual Scientific Session Reveals More Than 110,000 Cardiovascular Events a Year Could Occur in High-Risk Patients With Cardiovascular Disease who are Rejected Access Additional Study Calls for Assessment of Utilization Management Processes to Improve Access for Appropriate Patients and Prioritize Patients at the Highest Risk for Subsequent Cardiovascular Events THOUSAND OAKS, Calif., March 9, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced data from two new studies exploring barriers to access for PCSK9 inhibitors and the potential...
Source: Amgen News Release - March 9, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Final Results Of Tender Offer
THOUSAND OAKS, Calif., March 8, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the final results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of Monday, March 5, 2018. Amgen has accepted for purchase 52,083,333 shares of its common stock, $0.0001 par value per share, at a price of $192 per share, for an aggregate cost of approximately $10 billion, excluding fees and expenses relating to the tender offer. These shares represent approximately 7.2 percent of the shares outstanding. The tender offer was oversubscribed and pursuant to the terms o...
Source: Amgen News Release - March 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces 2018 Second Quarter Dividend
THOUSAND OAKS, Calif., March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.32 per share dividend for the second quarter of 2018. The dividend will be paid on June 8, 2018, to all stockholders of record as of the close of business on May 17, 2018. About Amgen Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand t...
Source: Amgen News Release - March 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present At the Cowen and Company 38th Annual Health Care Conference
THOUSAND OAKS, Calif., March 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 38th Annual Health Care Conference at 1:30 p.m. ET on Monday, March 12, 2018, in Boston. David W. Meline, executive vice president and chief financial officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event. About Amgen Amgen is committed to unlocking the potential of biology for patients s...
Source: Amgen News Release - March 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Preliminary Results Of Tender Offer
THOUSAND OAKS, Calif., March 6, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the preliminary results of its modified Dutch auction tender offer, which expired at 12:00 Midnight, New York City time, at the end of March 5, 2018. Based on the preliminary count by American Stock Transfer & Trust Company, LLC, the depositary for the tender offer, a total of 54,297,698 shares of Amgen's common stock, $0.0001 par value per share, were properly tendered and not properly withdrawn at or below the purchase price of $192 per share, including 33,745,174 shares that were tendered by notice of guaranteed delivery. Amg...
Source: Amgen News Release - March 6, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion For Delivery System Of Neulasta ® (pegfilgrastim)
Innovative Neulasta® Onpro® Kit is Designed to Provide the Right Dose for Patients at the Right Time THOUSAND OAKS, Calif., Feb. 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending a label variation for Neulasta® (pegfilgrastim) to include the Neulasta® Onpro® Kit. The Neulasta Onpro Kit combines the efficacy of Neulasta with an innovative on-body injector (OBI) delivery system. Neulasta is indicated in the European Union (EU) for the re...
Source: Amgen News Release - February 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New Data From Repatha ® (evolocumab) Clinical Trials At ACC.18
Presentations Focus on Patients With Established Cardiovascular Disease and Include Data Exploring Consistency of LDL-C Reduction With Repatha New Data Shows Patients at High Risk for Cardiovascular Events Continue to be Denied PCSK9 Inhibitors THOUSAND OAKS, Calif., Feb. 26, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from the Repatha® (evolocumab) clinical trial program to be featured at the American College of Cardiology's 67th Annual Scientific Session (ACC.18) in Orlando, Fla., March 10-12, 2018. Presentations to include additional analyses from the Repatha cardiovascular ou...
Source: Amgen News Release - February 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA ® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA® (denosumab) to cover skeletal-related events in patients with multiple myeloma. If approved, XGEVA will be indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bon...
Source: Amgen News Release - February 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces FDA Advisory Committee Meeting To Review Potential New Use Of BLINCYTO ® (blinatumomab)
First-Ever Application to be Submitted for an MRD Positive Indication THOUSAND OAKS, Calif., Feb. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) will review data supporting the BLINCYTO® (blinatumomab) supplemental Biologics License Application (sBLA) for the treatment of patients with minimal residual disease (MRD)-positive B-cell precursor acute lymphoblastic leukemia (ALL) at a meeting on March 7, 2018. MRD refers to the presence of a small amount of detectible cancer cells that remain in the patien...
Source: Amgen News Release - February 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news